Sino Biopharmaceutical Limited Share Price and Company Fundamentals
Last traded: Today at 8:08 AM
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Key Metrics
PE ratio
26.63
PB ratio
3.03
Dividend yield
1.56%
Beta
0.81
Market cap
$114.34B
Enterprise value
$118.83B
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 23056 |
| Website | https://www.sinobiopharm.com |
| Mailing address | Unit 09, Office Tower 41st Floor, Room 4109 Convention Plaza 1 Harbour Road Wan Chai Hong Kong |
| Phone / Fax | 852 2802 9886 / |
Dividends
Dividend yield
1.56%
Dividend amount
$0.10
Payout ratio
29.41%
5Y Avg. yield
-%
Sino Biopharmaceutical Limited paid $0.10 dividend and the ex-dividend date was 29 Aug 2025.The dividend payout ratio is 29.41%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.1177 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Sino Biopharmaceutical Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Ms. Y. Y. Tse | Executive Chairwoman of the Board | 33 | |
| Mr. S. Y. Tse | CEO & Executive Director | 29 | |
| Mr. Ping Tse | Founder & Senior Executive Vice Chairman | 73 | |
| Ms. Cheung Ling Cheng | Executive Vice Chairwoman of the Board | 61 | |
| Mr. Zhoushan Tian | Executive Director | 61 | |
| Mr. Hsin Tse | Senior VP & Executive Director | 55 | |
| Ms. Chun Ling Li | Chief Financial Officer | 53 | |
| Mr. Song Jin | Vice President of Public Affairs & ESG | 49 | |
| Mr. Toogood Ben | CEO of InvoX & Head of Globalization | 48 | |
| Ms. Kuen Lai | Company Secretary |
Profitability and management effectiveness
Profit margin
12.67%
Operating margin
19.39%
Return on assets
5.07%
Return on equity
15.40%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Sino Biopharmaceutical Limited is 114.34B and its enterprise value is 118.83B. The enterprise value to revenue ratio of 1177 is 3.89. The enterprise value to EBITDA ratio of 1177 is 17.27.
The 1177's stocks Beta value is 0.81 making it 19% less volatile compared to HKEX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Sino Biopharmaceutical Limited (HKEX:1177) Frequently Asked Questions
1. What is Sino Biopharmaceutical Limited's Stock Symbol?
Sino Biopharmaceutical Limited trades on HKEX under the ticker symbol "1177".
2. What is Sino Biopharmaceutical Limited's stock price today?
One share of 1177 stock can currently be purchased for approximately $6.39.
3. How can I contact Sino Biopharmaceutical Limited?
Sino Biopharmaceutical Limited's mailing address is Unit 09, Office Tower 41st Floor, Room 4109 Convention Plaza 1 Harbour Road Wan Chai Hong Kong. The company can be reached via phone at 852 2802 9886.
4. What is Sino Biopharmaceutical Limited's official website?
The official website of Sino Biopharmaceutical Limited is https://www.sinobiopharm.com.